Table 2. Characteristics of the whole population.
| Overall population n=553 | No recurrence n=462 | Recurrence n=91 | P-valuea | |
|---|---|---|---|---|
| Age-mean (range) | 64.9 (31–98) | 64.4 (31–98) | 67.8 (32–88) | 0.0033 |
|
Histological grade | ||||
| I | 48.6% (269) | 52.4% (242) | 29.7% (27) | |
| II | 27.5% (152) | 29.2% (135) | 18.7% (17) | |
| III | 23.9% (132) | 18.4% (85) | 51.6% (47) | <0.0001 |
|
Pathological type | ||||
| 1 | 86.6% (479) | 89.2(412) | 73.6% (67) | |
| 2 | 13.4% (74) | 10.8(50) | 26.7% (24) | 0.0001 |
|
Myometrial invasion | ||||
| <50% | 54.3% (300) | 58.4% (270) | 32.9% (30) | |
| ⩾50% | 45.7% (253) | 41.6% (192) | 67.1% (61) | <0.0001 |
|
Lymphovascular space invasion | ||||
| No | 66.4% (367) | 70.4% (325) | 46.1% (42) | |
| Yes | 25.3% (140) | 21.2% (98) | 46.1% (42) | |
| NA | 8.3% (46) | 8.4% (39) | 7.8% (7) | <0.0001 |
|
FIGO stage | ||||
| I | 78.1% (432) | 81.8% (378) | 59.3% (54) | |
| II | 7.6% (42) | 6.3% (29) | 14.3% (13) | |
| IIIc | 14.3% (79) | 11.9% (55) | 26.4% (24) | <0.0001 |
| Nodal staging (P/PAL) | 86.6% (479/553) | 87.1% (402/462) | 84.6% (77/91) | 0.0001 |
| Nodal metastasis | 16.5% (79/479) | 13.7% (55/402) | 31.2% (24/77) | 0.0001 |
|
PORTEC-1 (Creutzberg et al, 2000a) | ||||
| Low risk | 32% (175) | 35% (163) | 13% (12) | |
| Intermediate risk | 19% (106) | 21% (97) | 10% ( 9) | |
| High-intermediate risk | 24% (134) | 23% (105) | 32% ( 29) | |
| High risk | 25% (138) | 21% (97) | 45% ( 41) | — |
|
GOG-99 (Keys et al, 2004) | ||||
| Low risk | 51% (280) | 55% (255) | 27% (25) | |
| Low-intermediate risk | 2% (13) | 2% (10) | 3% (3) | |
| High-intermediate risk | 23% (129) | 23% (106) | 25% (23) | |
| High risk | 24% (131) | 20% (91) | 44% ( 40) | — |
|
SEPAL (Todo et al, 2010) | ||||
| Low risk | 43% (238) | 48% (221) | 19% (17) | |
| Intermediate risk | 43% (236) | 40% (186) | 55% (50) | — |
| High risk | 14% (79) | 12% (55) | 26% (24) | |
|
ESMO (Colombo et al, 2013) | ||||
| Low risk | 45.1% (249) | 50.4% (233) | 17.6% (16) | |
| Intermediate risk | 34.5% (191) | 34.0% (157) | 37.4% (34) | |
| High risk | 20.4% (113) | 15.6% (72) | 45.0% (41) | — |
|
ESMO/LVSI (Bendifallah et al, 2014) | ||||
| Low-risk ESMO/LVSI− | 37.6% (208) | 41.8% (193) | 16.5% (15) | |
| Low-risk ESMO/LVSI+ | 2.7% (15) | 3.2% (15) | 0% (0) | |
| Intermediate-risk ESMO/LVSI− | 18.8% (104) | 19.6% (90) | 15.4% (14) | |
| Intermediate-risk ESMO/LVSI+ | 13.2% (73) | 12.1% (56) | 18.7% (17) | |
| High-risk ESMO/LVSI− | 9.9% (55) | 9.1% (42) | 14.3% (13) | |
| High-risk ESMO/LVSI+ | 9.4% (52) | 5.8% (27) | 27.4% (25) | — |
| NA | 8.4% (46) | 8.4% (39) | 7.7% (7) | |
|
Adjuvant therapy | ||||
| No adjuvant therapy | 18.1% (100) | 20.1% (93) | 7.7% (7) | — |
| EBRT ± brachytherapy | 34.7% (192) | 30.8% (142) | 54.9% (50) | |
| Brachytherapy | 30.1% (166) | 34.8% (161) | 5.5% (5) | |
| Chemotherapy | 2.3% (13) | 0.9% (4) | 9.9% (9) | |
| Multimodal therapy | 4.9% (27) | 3.5% (16) | 12.1% (11) | |
| NA | 9.9% (55) | 9.9% (46) | 9.9% (9) | |
Abbreviations: EBRT=External beam radiotherapy; ESMO=European Society for Medical Oncology; FIGO=Federation of Gynecology and Obstetrics; GOG=Gynecologic Oncology Group; LVSI=lymphovascular space invasion; NA=not applicable; P/PAL=pelvic and/or paraaortic lymphadenectomy; PORTEC=Post Operative Radiation Therapy in Endometrial Carcinoma; SEPAL=Survival effect of para-aortic lymphadenectomy.
a
Univariate logistic regression.